PALVELLA THERAPEUTICS INC (PVLA) competitors & alternatives
Health Care · NASDAQ
PALVELLA THERAPEUTICS INC (PVLA)'s top competitors and alternatives — its most similar public companies — include Regeneron Pharmaceuticals (REGN), Incyte (INCY), WAVE LIFE SCIENCES LTD (WVE), CATALYST PHARMACEUTICALS INC (CPRX), LARIMAR THERAPEUTICS INC (LRMR), MAZE THERAPEUTICS INC (MAZE), FENNEC PHARMACEUTICALS INC (FENC), KINIKSA PHARMACEUTICALS INTERNATIO (KNSA), Jazz Pharmaceuticals (JAZZ), ZEVRA THERAPEUTICS INC (ZVRA), BIOCRYST PHARMACEUTICALS INC (BCRX) and XOMA ROYALTY CORP (XOMA). These are PALVELLA THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PVLA competitors & alternatives
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
IncyteINCYHealth Care
A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating…
$115.79 (as of 2026-07-22) · market cap $23.3B
-
WAVE LIFE SCIENCES LTDWVEHealth Care
A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex…
$5.74 (as of 2026-07-22) · market cap $1.1B
-
CATALYST PHARMACEUTICALS INCCPRXHealth Care
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from…
$31.49 (as of 2026-07-21) · market cap $3.9B
-
LARIMAR THERAPEUTICS INCLRMRHealth Care
Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the…
$4.02 (as of 2026-07-22) · market cap $418M
-
MAZE THERAPEUTICS INCMAZEHealth Care
Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease…
$28.49 (as of 2026-07-22) · market cap $1.6B
-
FENNEC PHARMACEUTICALS INCFENCHealth Care
Commercial-stage biopharma company bringing PEDMARK, the first and only approved drug to prevent cisplatin-induced ototoxicity in pediatric cancer patients, to…
$10.32 (as of 2026-07-22) · market cap $359M
-
KINIKSA PHARMACEUTICALS INTERNATIOKNSAHealth Care
Kiniksa is a biopharmaceutical company commercializing ARCALYST (IL-1 cytokine trap) for recurrent pericarditis and rare inflammatory diseases, with a pipeline…
$62.44 (as of 2026-07-22) · market cap $4.8B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
ZEVRA THERAPEUTICS INCZVRAHealth Care
Zevra brings life-changing therapies to ultra-rare neurodegenerative and metabolic diseases, with FDA-approved MIPLYFFA for Niemann-Pick disease type C now…
$12.14 (as of 2026-07-22) · market cap $762M
-
BIOCRYST PHARMACEUTICALS INCBCRXHealth Care
BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases…
$9.51 (as of 2026-07-22) · market cap $2.4B
-
XOMA ROYALTY CORPXOMAHealth Care
A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights…
$40.17 (as of 2026-07-21) · market cap $710M
Not quite? Describe exactly what you want →
Peers are PALVELLA THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PALVELLA THERAPEUTICS INC (PVLA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.